ArticleThe Journal of infectious diseases2025
Plasma Lipid Metabolites Differentiate Metabolic From Viral Chronic Liver Disease.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plasma gamma-glutamylglycine predicts the seroconversion of hepatitis B e antigen in patients with chronic hepatitis B.Frontiers in immunology · 2026Article
- Lysophosphatidylcholine as a Novel Diagnostic Biomarker in Kawasaki Disease: Based on Immunometabolism-Related Signature.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLipid metabolism is altered in human immunodeficiency virus (HIV) infection and chronic liver diseases, but common and unique pathways have not been elucidated, limiting prevention and treatment strategies. The aim of this study was to discover lipid metabolite signatures for persons with HIV (PWH), PWH with HCV coinfection (PWH-HCV), and individuals with metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD, MASH).
methodsPlasma metabolite profiling was performed in adult participants in 5 cohorts from a single center: PWH (n = 50), PWH-HCV (n = 50), HIV-negative biopsy-proven MASLD (n = 46), and MASH (n = 50), and controls without HIV or chronic liver disease (n = 29). Plasma metabolites were assessed using Biocrates Q500, bile acid, and oxylipin assays. Latent factor analysis along with unadjusted and adjusted logistic regression models were performed. Significance was defined as P value < .05 and false discovery rate < 0.10.
resultsCompared to controls, 457 of 816 measured metabolites were detected at different levels in PWH, 352 in PWH-HCV, 466 in MASLD, and 487 in MASH. Triglycerides and oxylipins were increased across disease states, but to a higher degree in PWH. PWH-HCV had a distinct metabolite signature with decreased ceramides and sphingomyelins. Levels of bile acid, amino acid, and fatty acid metabolites also differentiated cohorts.
conclusionsLipid metabolites demonstrated pathways common to, and unique to, HIV, HCV, and MASLD. Further studies will hopefully reveal the pathogenic role of these metabolites in liver disease severity, particularly in PWH with steatotic liver disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.